Osteocyte-derived Klotho vesicles mediate brain Klotho delivery and are gated by p16-driven senescence, linking bone aging to cognitive decline

Hypothesis

Age‑related increase in p16^INK4a^ expression in osteocytes suppresses secretion of Klotho‑containing extracellular vesicles (EVs). These EVs normally travel via the circulation to the brain, where they cross the blood‑brain barrier (BBB) through receptor‑mediated transcytosis (e.g., LRP2/megalin) to sustain neuronal Klotho signaling. Senescent osteocytes release fewer Klotho‑EVs, and the age‑associated shift of the BBB from selective to leaky transport further diminishes EV uptake, producing a brain‑specific Klotho deficit that drives neurodegeneration independent of systemic FGF23 levels.

Mechanistic Rationale

1. p16 regulates Klotho in bone – In klotho‑hypomorphic mice, p16 ablation restores Klotho expression and reverses aging phenotypes [3]. Osteocytes are long‑lived bone cells known to express p16 with age, providing a plausible site for transcriptional repression of Klotho.
2. Klotho‑EVs as a transport mode – Klotho can be secreted in exosomes that carry the protein to distant tissues. Bone‑derived EVs have been shown to deliver cargo to the brain via circulation [5], suggesting a viable route for endocrine Klotho delivery.
3. BBB selectivity loss – With aging, the BBB transitions from selective receptor‑mediated transcytosis to non‑specific leakiness, impairing uptake of specific cargoes such as Klotho‑EVs [4]. This creates a double hit: reduced supply and reduced uptake.
4. Brain Klotho protects neurons – Soluble Klotho exerts direct cardiovascular protection beyond its FGF23 co‑receptor role [2]; analogous neuroprotective actions have been reported (e.g., anti‑oxidant, synaptic preservation). A brain Klotho shortage would thus exacerbate age‑related cognitive decline.

Testable Predictions

• Prediction 1: Osteocyte‑specific p16 overexpression will reduce circulating Klotho‑EV levels and lower brain Klotho concentration, whereas osteocyte‑specific p16 deletion will increase brain Klotho even in aged animals.
• Prediction 2: Administration of purified osteocyte‑derived Klotho‑EVs to aged mice will rescue brain Klotho levels, improve synaptic markers, and attenuate cognitive deficits in behavioral assays (e.g., Morris water maze).
• Prediction 3: Blocking LRP2/megalin-mediated transcytosis at the BBB will abolish the cognitive benefits of osteocyte‑derived Klotho‑EVs, confirming the reliance on receptor‑mediated uptake.

Experimental Approach

1. Genetic models: Generate Osteo‑p16^OE^ and Osteo‑p16^KO^ mice (using Dmp1‑Cre). Measure plasma Klotho‑EV concentration (Western blot for Klotho in EV fractions), brain Klotho (ELISA of hippocampal lysates), and perform cognitive testing at 3, 12, and 24 months.
2. EV isolation and labeling: Isolate EVs from primary osteocytes (WT vs p16^OE^), label with fluorescent dye, inject intravenously, and track brain accumulation via imaging and histology.
3. BBB blockade: Treat mice with LRP2 antagonist (receptor-associated protein) or use Lrp2 heterozygous mice to assess impact of transcytosis inhibition on EV brain delivery and cognition.
4. Rescue studies: Inject purified osteocyte‑derived Klotho‑EVs into aged wild‑type mice; evaluate brain Klotho restoration, mitochondrial function in neurons (mtDNA copy number, ROS), and performance in learning/memory tasks.

Potential Confounds and Controls

• Systemic Klotho changes due to kidney contributions must be monitored; include kidney‑specific Klotho knock‑out controls to isolate bone‑derived effects.
• FGF23 levels should be measured to ensure observed effects are independent of the canonical axis.
• Use of aged-matched littermates and both sexes to account for variability.

Falsifiability

If osteocyte‑specific p16 manipulation does not alter circulating Klotho‑EV levels or brain Klotho, or if delivering osteocyte‑derived Klotho‑EVs fails to improve brain Klotho and cognition despite verified BBB transcytosis, the hypothesis would be falsified. Conversely, confirmation of the predicted chain (p16↑ → ↓osteocyte‑Klotho‑EVs → ↓brain Klotho → cognitive decline, reversible by EV replacement) would support a novel bone‑brain endocrine axis driving aging.